Biogen stumbles in crucial ALS study

Even though Biogen's drug candidate tofersen has not achieved its primary endpoint goal in an important phase III study of a particular sub-type of ALS, there are enough positive signs for the company to keep investigating next steps for the drug.

Brian Snyder/Reuters/Ritzau Scanpix | Photo: Brian Snyder/Reuters/Ritzau Scanpix

US-based biotech company Biogen has not managed to attain its primary endpoint goal in a crucial phase III study of its canditate tofersen, also called BIIB067, as a treatment for a specific type of ALS, SOD1-ALS, the firm reports in a press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs